Histone deacetylase inhibitors: understanding a new wave of anticancer agents

International Journal of Cancer. Journal International Du Cancer
Ana Villar-Garea, Manel Esteller

Abstract

Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease. The discovery that drastic changes in DNA methylation and histone modifications are commonly found in human tumors has inspired various laboratories and pharmaceutical companies to develop and study epigenetic drugs. One of the most promising groups of agents is the inhibitors of histone deacetylases (HDACs), which have different biochemical and biologic properties but have a single common activity: induction of acetylation in histones, the key proteins in nucleosome and chromatin structure. One of the main mechanisms of action of HDAC inhibitors is the transcriptional reactivation of dormant tumor-suppressor genes, such as p21WAF1. However, their pleiotropic nature leaves open the possibility that their well-known differentiation, cell-cycle arrest and apoptotic properties are also involved in other functions associated with HDAC inhibition. Many phase I clinical trials indicate that HDAC inhibitors appear to be well-tolerated drugs. Thus, the field is ready for rigorous biologic and clinical scrutiny to validate the therapeutic potential of these drugs. Our current data indicate that the use of HDAC inhibitors, probably in association with cla...Continue Reading

References

May 1, 1978·Cell·L Sealy, R Chalkley
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·S J Darkin-RattrayD M Schmatz
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·S Y ArcherR A Hodin
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·A SaitoO Nakanishi
Oct 6, 2000·Phytochemistry·J P MurphyW A Tramontano
Mar 30, 2001·Bioorganic & Medicinal Chemistry Letters·P J MurrayM R Elsegood
Jul 14, 2001·Nucleic Acids Research·M TakakuraM Inoue
Aug 11, 2001·Science·T Jenuwein, C D Allis
Dec 26, 2001·Proceedings of the National Academy of Sciences of the United States of America·A BedalovJ A Simon
Jan 25, 2002·International Journal of Cancer. Journal International Du Cancer·Mitsuhiro SuenagaShigeru Kohno
Mar 27, 2002·Anti-cancer Drugs·David M Vigushin, R Charles Coombes
Jul 16, 2002·Carcinogenesis·Esteban Ballestar, Manel Esteller
Jul 18, 2002·Nature Reviews. Drug Discovery·Ricky W Johnstone
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tsuyoshi ShojiHiromi Wada
Feb 6, 2003·International Journal of Cancer. Journal International Du Cancer·Junji TsurutaniShigeru Kohno
Feb 7, 2003·Current Drug Metabolism·Ana Villar-Garea, Manel Esteller
Apr 4, 2003·Current Opinion in Genetics & Development·Masayoshi Iizuka, M Mitchell Smith
Apr 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Stephen J HaggartyStuart L Schreiber
Apr 25, 2003·Trends in Genetics : TIG·Eric VerdinHerbert G Kasler
May 17, 2003·Cancer Biology & Therapy·Maria Eugenia Guicciardi, Gregory J Gores
May 29, 2003·Current Medicinal Chemistry. Anti-cancer Agents·Wei-Guo Zhu, Gregory A Otterson
Aug 6, 2003·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Claire M BanwellMoray J Campbell
Oct 10, 2003·The Journal of Biological Chemistry·Maki HiraoAntonio Bedalov
Jan 22, 2004·Proceedings of the National Academy of Sciences of the United States of America·C-Y GuiP A Marks

❮ Previous
Next ❯

Citations

May 9, 2006·Cancer Immunology, Immunotherapy : CII·Thomas B TomasiA Nazmul H Khan
Mar 21, 2012·Journal of Molecular Modeling·Michael Brunsteiner, Pavel A Petukhov
Sep 29, 2009·Modern Rheumatology·Reiji HigashiyamaHiroshi Asahara
Sep 13, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Sabina Pucci, Paola Mazzarelli
Oct 2, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Elisa M YorkA Jane Roskams
Jun 1, 2005·European Journal of Medicinal Chemistry·Patrick AngibaudMichel Janicot
Aug 26, 2006·Nature Clinical Practice. Neurology·Ghazaleh Sadri-Vakili, Jang-Ho J Cha
Jun 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·Luz E Tavera-MendozaJohn H White
Jan 3, 2012·Journal of Biomolecular Structure & Dynamics·Sundarapandian ThangapandianKeun Woo Lee
Oct 8, 2011·Developmental Neuropsychology·David L Molfese
Feb 22, 2007·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Nicholas D Allen
Apr 3, 2007·Acta Crystallographica. Section F, Structural Biology and Crystallization Communications·Tine Kragh NielsenRalf Ficner
Aug 24, 2005·International Journal of Clinical Practice·J Spicer, P Harper
Jun 11, 2005·International Archives of Allergy and Immunology·Kenji IshiharaKazuo Ohuchi
Apr 22, 2005·Clinical Chemistry and Laboratory Medicine : CCLM·João GonçalvesMiguel Brito
May 26, 2005·International Journal of Hematology·Frank M Raaphorst
Apr 10, 2010·Journal of the American Society of Nephrology : JASN·Eric D de GrohNeil A Hukriede
May 29, 2013·Pharmacology & Therapeutics·Ian F Harrison, David T Dexter
Apr 13, 2010·Bioorganic & Medicinal Chemistry·Stefania TerraccianoInes Bruno
Apr 16, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·José Christian Machado XimenesGlauce Socorro de Barros Viana
Aug 17, 2011·Journal of Biomedicine & Biotechnology·Guoqiang SunYanhong Shi
May 7, 2010·Metabolomics : Official Journal of the Metabolomic Society·Gema Alcarraz-VizánMarta Cascante
Aug 9, 2005·Expert Opinion on Therapeutic Targets·Roberto R Rosato, Steven Grant
Nov 26, 2005·Expert Opinion on Investigational Drugs·Paul A Marks, Milos Dokmanovic
Jul 27, 2006·Expert Opinion on Drug Metabolism & Toxicology·Eun Joo ChungJane B Trepel
Jul 4, 2012·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Shahrzad Soleymani FardAli M Ardekani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.